Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cholesterol drug
Biotech
Merck's oral PCSK9 inhibitor leader reduces cholesterol in ph. 3
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning.
James Waldron
Jun 9, 2025 9:00am
Verve posts clean PCSK9 editor profile, teeing up Lilly decision
Apr 14, 2025 7:00am
NewAmsterdam shares sign drug improves cardiovascular outcomes
Dec 10, 2024 8:48am
NewAmsterdam’s cholesterol ph. 3 hits, but disappoints investors
Nov 20, 2024 10:07am
YolTech sells China rights to gene editing therapy for $29M
Aug 27, 2024 10:24am
Chasing Merck, AstraZeneca's PCSK9 inhibitor lowers cholesterol
May 29, 2024 11:00am
